On Feb.11 Optimer completed a 6M share offering of common stock at a price of $11.25 sh. and the stock has held up well despite the dilution. On February 7 the Company announced a deal with Astellas Pharmaceutical licensing off rights to their Fidaxomycin C.diff drug for Europe, parts of Africa and the Mid East.A recent publication in NEJM.org said the drug is comparable to Vancomycin with a lower rate of recurrence. An FDA action date is expected by May 30. Another product -Pruvel- is in the Phase III pipeline for travelers diarrhea. The stock may be volatile but the upcoming approval milestone combined with the strong balance sheet augers well for the Company.
- Groups sue over Alabama abortion law; judge blocks Mississippi ban May 25, 2019
- Mexico budget cuts hit patient care and delay kids' surgeries, doctors warn May 24, 2019
- Novartis $2 million gene therapy for rare disorder is world's most expensive drug May 24, 2019
- Doctor, medical funder charged in New York in transvaginal mesh fraud May 24, 2019
2009-2017 Life Science Portfolios 2018 Rayno Biopharmaceuticals Portfolio 2018 Rayno Tools and Diagnostics Portfolio BIOgraph Biopharmaceuticals Clinical Diagnostics and Tools Energy Life Science ETF's and Mutual Funds Macro RAG Rayno Life Science Portfolio Reading List Weather//Ski Reports-Western US Weather Snow Reports West Coast